```json
{
"content": [
{
"type": "paragraph",
"content": "Over the past 18 months, the Traditional Chinese Medicine Compound Preparation industry trends have pivoted toward large-scale consolidation and digital therapeutics integration. Beijing Tongrentang’s $340 million buy-out of Anhui-based Hengchang Pharmaceutical in Q1 2023 created the first cross-province vertically integrated TCM chain, securing 42% of the domestic granule market overnight."
},
{
"type": "paragraph",
content: "Simultaneously, Shanghai Pharma, in partnership with Tencent Health, launched China’s first AI-driven TCM formulation platform (YunFang) in April 2024, reducing personalized decoction lead times from 48 hours to 90 minutes and attracting 1,300 hospitals within six months."
},
{
"type": "paragraph",
content: "Regulatory momentum accelerated when NMPA enacted the Pilot Compound Catalog in September 2023, fast-tracking 97 classical formulas and granting provincial-level approval autonomy—sparking a 28% YoY surge in new product filings."
},
{
"type": "paragraph",
content: "Consumer demand has shifted toward evidence-based convenience formats; sublingual micro-pellets grew 3× faster than traditional decoctions, accounting for 31% of OTC TCM sales on Tmall in 2023."
},
{
"type": "paragraph",
content: "Finally, global capital flowed in: Hong Kong’s Puzhen Group closed a $55 million Series B in January 2024 to build a GMP-compliant, carbon-neutral extraction hub in the Hengqin Guangdong-Macao Deep Cooperation Zone, targeting ASEAN exports from 2025 onward."
}
]
}
```
